Failure to initiate an SGLT2i to an eligible HFrEF patient exposes the patient to higher risk of early post-discharge death and readmission, and the real risk that the medication never gets prescribed at all. In this interview, Stephen J. Greene, MD and Christopher B. Granger MD, FACC, with Ioannis Mastoris, MD, MPH, discuss In-Hospital Initiation of Sodium Glucose Cotransporter-2 Inhibitors for Heart Failure with Reduced Ejection Fraction.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL